RIGI and acute myeloid leukemia: A library of potential RIG‐I‐inducing compounds is rationally constructed and screened, in which the approved M3 AML treatment drug tamibarotene (TAM) exhibits strikingly 28036‐fold selectivity and 779 pm IC50 in killing HMA‐resistant AML cells.